The Trond Mohn Foundation has newly awarded 18 millions NOK to three cancer research projects, one of which is HUVAMER-project “HUVAMER – Home Treatment for Blood Cancer” led by Professor Dr. med. Bjørn Tore Gjertsen.
The HUVAMER-project is aimed to develop a new combination of medications in treatment of acute myeloid leukemia (AML), with the goal of achieving a safe, cost-effective, and home-based treatment. Biological markers that indicate who benefits from the treatment will be identified for enabling more precise and effective therapy.
More information is found at: https://stiftelsesforeningen.no/aktuelt/trond-mohn-forskningsstiftelse-tildeler-18-millioner-til-kreftforskning.
NB